Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0122)
| Name |
Carboplatin
|
||||
|---|---|---|---|---|---|
| Synonyms |
41575-94-4; Carboplatin; Paraplatin; Cbdca; Carboplatinum; JM-8; MFCD00070464; NSC-241240; cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); 1,1-Cyclobutanedicarboxylate diammine platinum(II); NSC241240; cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; DTXSID3046742; CHEBI:31355; NSC-201345; Platinum(II),1-cyclobutanedicarboxylato)diammine-, cis-; Platinum,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-; Platinum,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-; Epitope ID:194801; SCHEMBL4964; 1,1-Cyclobutanedicarboxylatodiammineplatinum(II); Paraplatin (Bristol Meyers); Lopac0_000230; DTXCID201476080; HMS3269H03; Pharmakon1600-01502106; NSC201345; NSC758182; STL451040; Tox21_112586_1; NSC-758182; NCGC00167800-01; NCGC00263858-02; BP-25385; SY075575; CAS-41575-94-4; EN300-123065; AB01273939-01; azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+); 7,7-diamino-6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione; diamino[cyclobutane-1,1-dicarboxylato(2-)-kappa~2~O~1~,O~1~]platinum; Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-.kappa.O,.kappa.O'']-, (SP-4-2)-
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C6H12N2O4Pt
|
||||
| IUPAC Name |
azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
|
||||
| Canonical SMILES |
C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
|
||||
| InChI |
InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2
|
||||
| InChIKey |
VSRXQHXAPYXROS-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Cytochrome b-245 heavy chain (CYBB)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Driver | |||
| Responsed Disease | Ovarian cancer | ICD-11: 2C73 | ||
| Responsed Regulator | WW domain-containing transcription regulator protein 1 (WWTR1) | Driver | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Hippo signaling pathway | hsa04390 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | Caov-2 cells | Ovarian carcinoma | Homo sapiens | CVCL_6861 |
| TOV-21G cells | Ovarian clear cell adenocarcinoma | Homo sapiens | CVCL_3613 | |
| Response regulation | There is a significant correlation between the expression of ANGPTL4 and TAZ (encoded by WWTR1) in the TCGA ovarian tumor dataset. Carboplatin-treated CAOV2R cells are less sensitive to ferroptosis and have a lower level of TAZ (TAFAZZIN). TAZ promotes ferroptosis in ovarian cancers by regulating ANGPTL4 and NOX2, offering a novel therapeutic potential for ovarian tumors with TAZ activation. | |||